Immunotherapy agents for treatment of cancer have been investigated for decades, but effective agents have only recently been identified and are increasingly being used in multiple cancer types. There is growing recognition of adverse side effects in multiple organ systems mediated by dysregulation of the immune system, which can be exacerbated by co-morbidities often found in cancer patients such as chronic lung disease, diabetes, and hypertension. As a result, internists and other non-oncology clinicians are routinely encountering immunotherapy patients who present with a remarkably wide range of symptoms.